Pharmaceutical Industry in the
Canton of Geneva

Telix Pharmaceuticals (Switzerland) Sàrl

Since 1999 · 21–50 empl.

The core activity of Telix Pharmaceuticals is the development and manufacture of biopharmaceutical products, in particular targeted radiation products for the diagnosis and treatment of cancer and rare diseases.

Botavie SA

Since 2000 · 1–10 empl.

Botavie SA offers plant-based dietary supplements and health products formulated according to the Unani tradition and markets them online under the BOTAVIE and IRELIA brands.

Addex Pharma SA

Since 2002 · 1–10 empl.

Addex Pharma SA is a clinical-stage pharmaceutical company focused on the development and commercialization of orally available small-molecule allosteric modulators for neurological disorders. Its pipeline includes programs such as dipraglurant (mGlu5 NAM), ADX71149 (mGlu2 PAM) and GABAB PAM candidates targeting indications including substance use disorder and chronic cough.

Desaturase SA

Since 2003 · 1–10 empl.

The core activity of Desaturase SA is the development, manufacture and marketing of dietary supplements, particularly vitamins, minerals and other nutrients in the form of capsules, gelules and powders.

Epithelix Sàrl

Since 2006 · 11–20 empl.

Epithelix Sàrl develops and supplies in vitro reconstituted human respiratory tissue models and associated culture media, including MucilAir™, SmallAir™ and AlveolAir™. The company also provides laboratory testing services (CRO), such as viral and bacterial infection assays, inhalation toxicity testing, nasal spray evaluation and mucociliary endpoint analyses.

Laboratoires Elveapharma Sàrl

Since 2008 · 11–20 empl.

The core activity of Elveapharma is the development, manufacture and marketing of natural food supplements and health products, particularly in the area of sleep and sun protection products. The company offers a range of products based on natural ingredients such as L-tryptophan, vitamins and green tea, which are sold in pharmacies, parapharmacies and drugstores.

Bionoltra SA

Since 2008 · 11–20 empl.

The core activity of BIONOLTRA SA is the development, manufacture and marketing of medical devices and products for orthopedics and urology, particularly for the treatment of osteoarthritis and other diseases affecting the musculoskeletal system and urology.

SOLID Drug Development SA

Since 2010 · 1–10 empl.

The core activity of Solid Drug Development is strategic and operational consulting for the development of biotech and pharmaceutical products. Specifically, the company supports the development of medicines from the laboratory phase to clinical testing and helps reduce costs and operational problems for pharmaceutical companies.

EHC (EUROPEAN HEALTH CORPORATION) SA

Since 2010 · 1–10 empl.

EHC (EUROPEAN HEALTH CORPORATION) SA develops and commercializes consumer healthcare and self-care products, including OTC medicines, medical devices and dietary supplements. The company conducts acquisitions, in-/out-licensing, distribution and brand promotion, and partners with distributors and laboratories to bring its products to market.

VASPERIS SA

Since 2010 · 11–20 empl.

O'TENTIKA is a cosmetics company specializing in the manufacture and distribution of skin and facial care products. The company's core activity encompasses the development, production, and sale of premium skin care products, particularly in the field of skin refinement and care.

CROSS PHARM SA

Since 2013 · 1–10 empl.

The core activity of Cross Pharm S.A. is the development, manufacture and marketing of high-quality medicines, including antibiotics, antiemetics, muscle relaxants, orexigenics and vitamins as well as minerals.

APTISSEN SA

Since 2013 · 51–100 empl.

Aptissen develops and distributes medical products, particularly orthobiological solutions for the treatment of muscle and joint pain. The company's core activities include research, development and marketing of products such as Synolis VA and Cartylis, which are used for tissue regeneration and repair.

ReMedys Foundation

Since 2013 · 11–20 empl.

The core activity of ReMedys is to develop and promote innovative therapeutic approaches for patients with severe diseases without effective treatment, regardless of their commercial potential. To this end, ReMedys works in partnership with academic research institutions and industry experts to translate research results into clinical trials and develops new medicines in a project-based approach.

Ageronix SA

Since 2013 · 1–10 empl.

Ageronix's core activity is the development of treatments for neurodegenerative diseases, particularly using the protein Alpha 1 Anti-Trypsin (AAT). The company focuses on researching and developing therapies for rare neurological disorders, such as Charcot-Marie-Tooth disease (CMT), and has already completed preclinical developments and plans to initiate clinical trials in 2024.

Bailleul (Suisse) SA

Since 2014 · 11–20 empl.

Bailleul (Suisse) SA is a pharmaceutical company specializing in the development and commercialization of medicinal products, dietary supplements and dermo‑cosmetic products.

ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA

Since 2014 · 11–20 empl.

The core activity of Advanced Accelerator Applications (AAA) is the development and delivery of products and services in the field of nuclear medicine, particularly in the areas of radioligand therapy (RLT) and molecular imaging with positron emission tomography (PET).

Santen SA

Since 2014 · 101–500 empl.

The company's core activity is the development, manufacture and marketing of pharmaceutical products in the field of ophthalmology, with the aim of developing innovative and effective solutions for the treatment of eye diseases and providing added value to patients and society.

DermAbiotech Sàrl

Since 2014 · 1–10 empl.

DermAbiotech Sàrl develops targeted therapies for acute T cell–mediated inflammatory diseases. The company focuses on therapeutic candidates designed to modulate T‑cell driven inflammation.

SYRHATECH SA

Since 2015 · 11–20 empl.

Syrhatech SA is a Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of formulations for the cosmetics and pharmaceutical industries. The core activities include research and development (R&D), formulation, manufacturing and analysis of products. The company also offers technology transfer and batch manufacturing for clients.

CELL RECEPTOR SA

Since 2015 · 1–10 empl.

CELL RECEPTOR SA develops a novel cell-biology-based therapy for cancer and autoimmune diseases. It researches an extracellular signalling mechanism and develops compounds that block interactions between tumour cells and platelets to reduce tumour growth, metastasis and chemoresistance.

Kyowa Kirin Sàrl

Since 2016 · 21–50 empl.

The core activity of Krystal Biotech, Inc. is the development and manufacture of pharmaceuticals, particularly biopharmaceuticals. The company focuses on the research and development of new therapeutics based on genetic and biotechnological methods. The company's products aim to treat various diseases and conditions, including rare genetic disorders.

Atopia Therapeutics SA

Since 2016 · 1–10 empl.

Atopia Therapeutics SA is developing a disease‑modifying therapy for asthma and other allergic diseases. Its lead candidate, ATP‑R13, is a patented recombinant protein derived from a Helicobacter pylori molecule intended for oral administration to modulate immune tolerance and reduce inflammation; the company holds an exclusive worldwide licence from the University of Zurich and is conducting IND‑enabling activities.

STALICLA SA

Since 2017 · 11–20 empl.

STALICLA SA is a biopharmaceutical company developing precision medicines and clinical programs for neurodevelopmental and neuropsychiatric disorders. It uses the DEPI neuro-precision platform, combining multi-omics, patient data and AI to identify subgroups and match patients with drug treatments.

iOnctura SA

Since 2017 · 21–50 empl.

The core activity of iOnctura is the development of cancer drugs, particularly in oncology immunotherapy, with a focus on solid tumors, uveal melanoma and other types of cancer.

Gliapharm SA

Since 2017 · 11–20 empl.

Gliapharm SA develops medicines that target glial cells to enhance brain energy metabolism and support neuronal function. The company uses its GliaX™ discovery platform to identify molecular targets and small‑molecule candidates and advances preclinical translational models and biomarkers.

Relief Therapeutics International SA

Since 2018 · 21–50 empl.

Relief Therapeutics International SA develops therapeutic solutions in neurotherapy and digital rehabilitation. The company offers combined approaches that use software, devices, data, and behavior-based applications for therapy and monitoring.

Pharmex SA

Since 2018 · 51–100 empl.

The company's core activity encompasses the development, manufacture, and marketing of products and services in the following areas: * Pharmaceuticals: development and manufacture of medicines and medical devices, including generics and OTC products * Cosmetics: development and manufacture of premium cosmetic products for the general consumer and pediatric care * Dietary supplements: development and manufacture of dietary supplements (Food Supplements) * Services: provision of Contract Manufacturing Organization (CMO) services for pharmaceuticals, cosmetics, and biocides, as well as research and development (R&D) services for these areas. Thus, the company offers a wide range of products and services focusing on the areas of health, beauty, and wellness.

Vaccine Formulation Institute SA

Since 2020 · 21–50 empl.

The core activity of Vaccine Formulation Institute (VFI) is the development and provision of adjuvants and vaccine formulations for global health. The company supports the vaccine community by providing adjuvants and formulation expertise, supports the development of adjuvanted vaccines up to industrial scale, and helps donors and funders implement vaccine development programs.

argenx Switzerland SA

Since 2020 · 11–20 empl.

argenx Switzerland SA is a biopharmaceutical company that discovers, develops and commercializes antibody-based therapies for severe autoimmune diseases. Its portfolio includes the FcRn-targeting agent efgartigimod (marketed as VYVGART and VYVGART Hytrulo), a pipeline of additional antibody candidates such as empasiprubart, and ongoing clinical research.

CDC LAB SA

Since 2021 · 11–20 empl.

The core activity of CDC LAB SA is the production and distribution of medical cannabis and related products, in particular dried flowers and pharmaceutical active ingredients, which are manufactured under strict quality controls and GMP guidelines. The company also provides consulting services to healthcare professionals and pharmacies regarding the use and application of medical cannabis.

SUBSTIPHARM BIOLOGICS SA

Since 2022 · 11–20 empl.

The core activity of Substipharm is the development, manufacture and marketing of pharmaceuticals, including branded and generic products, as well as biological products and vaccines.

Topotarget Switzerland SA

Since 1999 · 1–10 empl.

Release Therapeutics SA

Since 2005 · 1–10 empl.

The core activity of Relief Therapeutics is the development and marketing of new, patented therapeutics for rare and ultra-rare diseases, particularly for patients with severe illnesses for which there are currently no or only limited treatment options. The company focuses on developing medications for specific diseases such as Epidermolysis Bullosa, Phenylketonuria and other rare conditions.

Advanced Biotech Laboratories Switzerland SA

Since 2010 · 21–50 empl.

The core activity of Advanced Biotech Laboratories Switzerland SA is the selection and promotion of high-quality anti-aging products and luxury health services, particularly in the field of cell therapy and stem cell research. The company collaborates with various clinics and laboratories to offer innovative products and services in the field of health and beauty.

Atheris SA

Since 2012 · 11–20 empl.

Atheris SA is a life sciences company listed on the BioAlps platform as part of the Western Switzerland ecosystem. The accessible page does not provide further details about its products, services, or core activities.

Geneva Biotech Center (GBC) SA

Since 2013 · 11–20 empl.

The core activity of Atopia Tx is the development of innovative therapies for asthma and allergic diseases, in particular the development of a first disease-modifying therapeutic for asthma and allergies based on a molecule from Helicobacter pylori.

Life Episteme Group Sàrl

Since 2013 · 1–10 empl.

PhytoCloud SA

Since 2017 · 1–10 empl.

PhytoCloud SA sells cannabis-derived THC and CBD products such as vape pods, e-liquids, cartridges and olfactory inhalers. The company also offers wholesale and white-label services and personal product formulation, working with Swiss laboratories.